HopeStage
Back to all studies
TerminatedNCT00771134

Efficacy and Safety of Lu AA39959 in Patients With Depression in bipolarity

Researchers are comparing Lu AA39959, placebo and Quetiapine to find out how the approaches affect depression symptoms in people with bipolarity type I or II.

Medication studyAges 18–65United States
The study in practice

Understand this study

What is this study about?

Researchers are comparing Lu AA39959, placebo and Quetiapine to find out how the approaches affect depression symptoms in people with bipolarity type I or II.

Who could participate?

This study is for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Listed locations
AtlantaSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateDecember 2008
Recruitment status
Terminated
Enrollment listed in the registry
105
Sponsor
H. Lundbeck A/S
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00771134
Official title
Show the full official title

Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Quetiapine-Referenced, Fixed-Dose Study of Lu AA39959 in the Treatment of Depression in Patients With Bipolar I or II Disorder

Recruitment & locations

Terminated

Atlanta

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

Researchers are comparing Lu AA39959, placebo and Quetiapine to find out how the approaches affect depression symptoms in people with bipolarity type I or II.

Who is behind this study?

The study sponsor is H. Lundbeck A/S.

Does this study involve medication?

Yes. The study involves medication, including Lu AA39959, Placebo and Quetiapine.

Who can participate?

This study is for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies